GULP1 as a Downstream Effector of the Estrogen Receptor-β Modulates Cisplatin Sensitivity in Bladder Cancer

被引:0
作者
Tatenuma, Tomoyuki [1 ,2 ]
Matsukawa, Takuo [1 ,2 ]
Goto, Takuro [1 ,2 ]
Jiang, Guiyang [1 ,2 ]
Sharma, Adhya [1 ,2 ]
Najafi, Mohammad amin elahi [1 ,2 ]
Teramoto, Yuki [1 ,2 ]
Miyamoto, Hiroshi [1 ,2 ,3 ,4 ]
机构
[1] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, 601 Elmwood Avenue,Box 626, Rochester, NY 14642 USA
[2] Univ Rochester, James P Wilmot Canc Inst, Med Ctr, Rochester, NY USA
[3] Univ Rochester, Med Ctr, Dept Urol, Rochester, NY USA
[4] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD USA
关键词
Bladder cancer; chemotherapy; cisplatin; estrogen receptor-beta; GULP1; ANDROGEN RECEPTOR; EXPRESSION;
D O I
10.21873/cgp.20472
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Precise molecular mechanisms underlying resistance to cisplatin-based chemotherapy remain unclear, while the activity of estrogen receptor-/3 (ER/3) has been suggested to be associated with chemosensitivity in urothelial cancer. We aimed to determine if GULP1, an adapter protein known to facilitate phagocytosis, could represent a downstream effector of ER/3 and thereby modulate cisplatin sensitivity in bladder cancer. Materials and Methods: GULP1 expression and cisplatin cytotoxicity were compared in bladder cancer lines. Immunohistochemistry was used to determine the expression of GULP1 and ER/3 in two sets of tissue microarray (TMA) consisting of transurethral resection specimens. Results: The levels of GULP1 expression were considerably higher in ER/3- knockdown sublines than in the respective control ER/3-positive sublines. Estradiol treatment reduced GULP1 expression in ERa-negative/ER/3-positive lines, which was restored by the anti- estrogen tamoxifen. Chromatin immunoprecipitation assay revealed the binding of ER/3 to the GULP1 promoter in bladder cancer cells. Moreover, GULP1 knockdown sublines were significantly more resistant to cisplatin treatment, but not to other chemotherapeutic agents, including gemcitabine, methotrexate, vinblastine, and doxorubicin. In the first set of TMA (n=129), the expression of ER/3 and GULP1 was inversely correlated (p=0.023), and ER/3(-)/GULP1(+) in 51 muscle- invasive tumors was associated with significantly lower risk of disease progression and cancer-specific mortality. Similarly, in the second set (n=43), patients with ER/3(-)/GULP1(+) muscle- invasive disease were significantly (p=0.021) more likely to be responders to cisplatin-based neoadjuvant chemotherapy before radical cystectomy. Conclusion: ER/3 activation was found to reduce the expression of GULP1 as a direct downstream target in bladder cancer cells, resulting in the induction of cisplatin resistance.
引用
收藏
页码:557 / 565
页数:9
相关论文
共 50 条
  • [21] miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells
    M T M van Jaarsveld
    J Helleman
    A W M Boersma
    P F van Kuijk
    W F van IJcken
    E Despierre
    I Vergote
    R H J Mathijssen
    E M J J Berns
    J Verweij
    J Pothof
    E A C Wiemer
    Oncogene, 2013, 32 : 4284 - 4293
  • [22] Notch-1 activates estrogen receptor-α-dependent transcription via IKKα in breast cancer cells
    Hao, L.
    Rizzo, P.
    Osipo, C.
    Pannuti, A.
    Wyatt, D.
    Cheung, L. W-K
    Sonenshein, G.
    Osborne, B. A.
    Miele, L.
    ONCOGENE, 2010, 29 (02) : 201 - 213
  • [23] miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells
    van Jaarsveld, M. T. M.
    Helleman, J.
    Boersma, A. W. M.
    van Kuijk, P. F.
    van IJcken, W. F.
    Despierre, E.
    Vergote, I.
    Mathijssen, R. H. J.
    Berns, E. M. J. J.
    Verweij, J.
    Pothof, J.
    Wiemer, E. A. C.
    ONCOGENE, 2013, 32 (36) : 4284 - 4293
  • [24] IDO1 Modulates the Sensitivity of Epithelial Ovarian Cancer Cells to Cisplatin through ROS/p53-Dependent Apoptosis
    Wang, Houmei
    Luo, Yuanyuan
    Ran, Rui
    Li, Xinya
    Ling, Hongjian
    Wen, Fang
    Yu, Tinghe
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
  • [25] The expression of platelet-activating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: a novel target for combination therapy
    Yu, Y.
    Zhang, X.
    Hong, S.
    Zhang, M.
    Cai, Q.
    Zhang, M.
    Jiang, W.
    Xu, C.
    BRITISH JOURNAL OF CANCER, 2014, 111 (03) : 515 - 524
  • [26] NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response
    Y Zhang
    Y Cheng
    X Ren
    L Zhang
    K L Yap
    H Wu
    R Patel
    D Liu
    Z-H Qin
    I-M Shih
    J-M Yang
    Oncogene, 2012, 31 : 1055 - 1064
  • [27] NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response
    Zhang, Y.
    Cheng, Y.
    Ren, X.
    Zhang, L.
    Yap, K. L.
    Wu, H.
    Patel, R.
    Liu, D.
    Qin, Z-H
    Shih, I-M
    Yang, J-M
    ONCOGENE, 2012, 31 (08) : 1055 - 1064
  • [28] The expression of platelet-activating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: a novel target for combination therapy
    Y Yu
    X Zhang
    S Hong
    M Zhang
    Q Cai
    M Zhang
    W Jiang
    C Xu
    British Journal of Cancer, 2014, 111 : 515 - 524
  • [29] Estrogen receptor-α directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer
    Yang, Jun
    AlTahan, Alaa
    Jones, Dylan T.
    Buffa, Francesca M.
    Bridges, Esther
    Interiano, Rodrigo B.
    Qu, Chunxu
    Vogt, Nathan
    Li, Ji-Liang
    Baban, Dilair
    Ragoussis, Jiannis
    Nicholson, Robert
    Davidoff, Andrew M.
    Harris, Adrian L.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (49) : 15172 - 15177
  • [30] Estrogen receptor-α regulation of microRNA-590 targets FAM171A1-a modifier of breast cancer invasiveness
    Sanawar, Rahul
    Dan, Vipin Mohan
    Santhoshkumar, Thankayyan R.
    Kumar, Rakesh
    Pillai, M. Radhakrishna
    ONCOGENESIS, 2019, 8 (1)